ES2249042T3 - Pge sintasa y procedimientos y medios para la modulacion de su actividad. - Google Patents

Pge sintasa y procedimientos y medios para la modulacion de su actividad.

Info

Publication number
ES2249042T3
ES2249042T3 ES99957275T ES99957275T ES2249042T3 ES 2249042 T3 ES2249042 T3 ES 2249042T3 ES 99957275 T ES99957275 T ES 99957275T ES 99957275 T ES99957275 T ES 99957275T ES 2249042 T3 ES2249042 T3 ES 2249042T3
Authority
ES
Spain
Prior art keywords
polypeptide
pge
pge synthase
sec
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99957275T
Other languages
English (en)
Spanish (es)
Inventor
Per-Johan Jakobsson
Bengt Samuelsson
Ralf Morgenstern
Anthony Ford-Hutchinson
Joseph Mancini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karolinska Innovations AB
Original Assignee
Karolinska Innovations AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations AB filed Critical Karolinska Innovations AB
Application granted granted Critical
Publication of ES2249042T3 publication Critical patent/ES2249042T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
    • G01N33/553—Metal or metal coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
ES99957275T 1998-11-09 1999-11-02 Pge sintasa y procedimientos y medios para la modulacion de su actividad. Expired - Lifetime ES2249042T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10768798P 1998-11-09 1998-11-09
US107687P 1998-11-09

Publications (1)

Publication Number Publication Date
ES2249042T3 true ES2249042T3 (es) 2006-03-16

Family

ID=22317930

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99957275T Expired - Lifetime ES2249042T3 (es) 1998-11-09 1999-11-02 Pge sintasa y procedimientos y medios para la modulacion de su actividad.

Country Status (9)

Country Link
US (4) US6395502B1 (enExample)
EP (1) EP1129188B1 (enExample)
JP (2) JP4503849B2 (enExample)
AT (1) ATE305040T1 (enExample)
AU (1) AU770307B2 (enExample)
CA (1) CA2349529C (enExample)
DE (1) DE69927400T2 (enExample)
ES (1) ES2249042T3 (enExample)
WO (1) WO2000028022A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69927400T2 (de) * 1998-11-09 2006-06-29 Karolinska Innovations Ab Pge synthase und verfahren und mitteln zur modulation deren aktivität
WO2001057225A1 (fr) * 2000-02-03 2001-08-09 Chugai Seiyaku Kabushiki Kaisha Proteine regissant l'activite de la pge2 synthase et son utilisation
JP2005526483A (ja) * 2001-08-24 2005-09-08 ファイザー・プロダクツ・インク 精製されたプロスタグランジンｅシンターゼを調製するための方法
KR20040062981A (ko) * 2001-11-30 2004-07-09 화이자 프로덕츠 인크. 프로스타글란딘 ｅ 합성효소 ２ 유전자의 붕괴
US20040132063A1 (en) * 2002-09-25 2004-07-08 Gierse James K. Antisense modulation of microsomal prostaglandin E2 synthase expression
WO2004067766A1 (en) * 2003-01-27 2004-08-12 Pfizer Products Inc. Novel methods involving the determination of activity of enzymes that use or produce prostaglandin endoperoxide h2
EP1673468A2 (en) * 2003-09-09 2006-06-28 Karolinska Innovations AB Methods for identifying compounds for inhibiting fever
US7638331B2 (en) 2004-01-02 2009-12-29 The Administration of the Tulane Rducation Fund Directed apoptosis in COX-2 overexpressing cancer cells through expression targeted gene delivery
CA2639412A1 (en) * 2007-09-11 2009-03-11 Universite Laval Prostaglandin e2 modulation and uses thereof
CN117323320B (zh) * 2023-11-20 2025-10-31 复旦大学附属中山医院 长链脂肪酸12-hht在睡眠呼吸暂停合并高血压中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US914356A (en) * 1901-11-30 1909-03-02 Harry Ward Leonard Electric-circuit controller.
AU750187B2 (en) * 1997-09-17 2002-07-11 Johns Hopkins University, The P53-induced apoptosis
DE69927400T2 (de) * 1998-11-09 2006-06-29 Karolinska Innovations Ab Pge synthase und verfahren und mitteln zur modulation deren aktivität

Also Published As

Publication number Publication date
AU1504100A (en) 2000-05-29
US7192733B2 (en) 2007-03-20
ATE305040T1 (de) 2005-10-15
US20080153107A1 (en) 2008-06-26
EP1129188A1 (en) 2001-09-05
CA2349529A1 (en) 2000-05-18
US6395502B1 (en) 2002-05-28
EP1129188B1 (en) 2005-09-21
CA2349529C (en) 2009-10-27
US7645601B2 (en) 2010-01-12
DE69927400T2 (de) 2006-06-29
AU770307B2 (en) 2004-02-19
US7067296B2 (en) 2006-06-27
DE69927400D1 (de) 2006-02-02
US20050118696A1 (en) 2005-06-02
JP2002539762A (ja) 2002-11-26
US20030064493A1 (en) 2003-04-03
JP4503849B2 (ja) 2010-07-14
WO2000028022A1 (en) 2000-05-18
JP2010115205A (ja) 2010-05-27

Similar Documents

Publication Publication Date Title
US7645601B2 (en) Methods and means for modulating PGE synthase activity
Jakobsson et al. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target
US5948664A (en) PI 3-kinase polypeptides
JP2004081211A (ja) ヒトシクロオキシゲナーゼ−２ｃＤＮＡ及びシクロオキシゲナーゼ−２の阻害を評価するアッセイ
US6015692A (en) CDC37 cell-cycle regulatory protein and uses related thereto
ES2279647T3 (es) Reguladores mitogenicos.
US6958238B2 (en) Isolated dishevelled associated kinases, polynucleotides encoding the kinases, and methods of use thereof
Grimm et al. Genomic organization and embryonic expression of Suppressor of Fused, a candidate gene for the split‐hand/split‐foot malformation type 3
AU2003271297B2 (en) PGE synthase and methods and means for modulating its activity
JP2002511764A (ja) Ｐａｋキナーゼ遺伝子およびポリペプチドならびにそれらの使用方法
ES2283060T3 (es) Marcador de seleccion.
WO2002031163A1 (en) Novel adamts family polypeptide and gene encoding the same
AU2001264596A1 (en) Novel dual oxidases as mitogenic and endocrine regulators
WO2001087957A2 (en) Novel dual oxidases as mitogenic and endocrine regulators
US6362327B1 (en) High level expression of human cyclooxygenase-2
CA2442772A1 (en) Isolated human nadph oxidase, nucleic acid molecules encoding said proteins, and uses thereof
WO1996040767A2 (en) E6ap-binding proteins
ES2342603T3 (es) Ciclooxigenasa-3-humana y usos de la misma.
US6468774B1 (en) Isolated human enzyme proteins, nucleic acid molecules encoding human enzyme proteins, and uses thereof
US7452974B2 (en) Isolated human squalene synthase and composition thereof
WO2002099110A1 (en) Cell cycle regulatory factor
MXPA98004934A (en) Diagnosis and treatment of alterations related to aur-1 and / or au